[Intravitreal anti-VEGF injections improve the visual prognosis of wet age related macular degeneration].
Age related macular degeneration (AMD) is an ocular disease with high prevalence among elderly persons. Two different forms exist: dry AMD, usually slowly progressive, and neovascular AMD (wet form) more aggressive. Photodynamic therapy is used to treat the wet form and anti VEGF treatments recently became available and offer a real change in the prognostic of wet AMD. Two products are registered and used in Switzerland (Macugen and Lucentis), a third "off labels product", Avastin is also currently used in clinical practice. Nevertheless, both the duration of treatment and the number of injection requested to stabilise the disease were not defined in the studies. Ongoing studies are mainly evaluating combined treatments and long acting form of the drug.
Ambresin
Aude
A
Unité de rétine médicale, Hôpital ophtalmique universitaire Jules Gonin, Av. de France 15, Lausanne. aude.ambresin@ophtal.vd.ch
Mantel
Irmela
I
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D011379:Prognosis; D000069579:Ranibizumab; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042442:Vascular Endothelial Growth Factors; D000069579:Ranibizumab